ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seres Therapeutics will collaborate with the Mayo Clinic’s Center for Individualized Medicine to develop microbiome-based therapeutics for liver diseases. The partners will look for treatments for primary sclerosing cholangitis, a bile duct disorder, and study the role of the microbiome in nonalcoholic steatohepatitis. Separately, Vedanta Biosciences, another firm trying to develop therapeutics to modulate the microbiome, has raised $50 million. The funding round, which will support several clinical studies, was led by PureTech, Rock Springs Capital, Invesco Asset Management, and Health for Life Capital.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter